Sarepta schedules third-quarter results. TD Cowen targets Sarepta Therapeutics stock at USD 17

Published on 10/25/2026 at 13:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue fell 34.30 percent to USD 401.25 million. Sarepta Therapeutics stock has a USD 17.00 TD Cowen target.

Upcoming results and pipeline data

Sarepta scheduled third-quarter results for November 5, 2026, after the Nasdaq close.
Second-quarter revenue was USD 401.25 million, while consensus expects USD 352.20 million for the third quarter.
SRPT had a USD 1.9 billion market capitalization as of October 23, 2026.

SRPT, US8036071004, Illustration mit AI erstellt.

Sarepta Therapeutics (ISIN US8036071004) scheduled its third-quarter 2026 results for November 5, 2026, after the Nasdaq close, according to Sarepta Therapeutics on October 22, 2026. TD Cowen maintained a Hold rating and a USD 17.00 price target on October 21, 2026, Markets Insider reported.

Pipeline data add a second test

Sarepta's most recent research update came on October 14, 2026, when the company presented preclinical SRP-1003 data for myotonic dystrophy type 1. The treatment achieved up to 80.00 percent knockdown of pathogenic DMPK messenger RNA in both the nucleus and cytoplasm in a preclinical model, according to Sarepta Therapeutics. The company also said the compound remained detectable across multiple muscle groups for up to 16 weeks after one intravenous dose.

The data are early-stage evidence rather than clinical efficacy. Sarepta said results from its ongoing Phase 1/2 study are expected later in 2026, making the November reporting date relevant for both financial performance and pipeline timing.

What does the next report mean for estimates?

MarketBeat's November 5, 2026 earnings preview puts third-quarter consensus revenue at USD 352.20 million, versus USD 399.36 million in the prior-year quarter, a projected decline of 11.80 percent. The same preview lists consensus earnings per share of USD 0.07 and notes that Sarepta reported USD 0.64 adjusted earnings per share in the second quarter, beating the USD 0.22 consensus estimate.

Three events frame the story

On August 5, 2026, Sarepta reported second-quarter revenue of USD 401.25 million and a GAAP net loss of USD 4.89 million, compared with revenue of USD 611.09 million and net profit of USD 196.89 million in the prior-year quarter, according to Markets Insider. On October 14, 2026, the company presented SRP-1003 data showing up to 80.00 percent DMPK knockdown. On October 22, 2026, it set November 5, 2026, for third-quarter results.

The next scheduled date is November 5, 2026, for third-quarter results, followed by a conference call at 4:30 p.m. ET. For investors, the central comparison is whether quarterly revenue can stabilize after the second-quarter year-over-year decline while the siRNA pipeline advances.

Stock context stays tied to execution

Sarepta's market capitalization was USD 1.9 billion as of October 23, 2026, with a 52-week range of USD 14.68 to USD 24.68. The valuation leaves clinical evidence and commercial revenue as the two measurable tests for the upcoming results.

The further course of trading is shown by the continuously updated real-time quote of Sarepta Therapeutics stock.